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Eosinophils in the bronchial mucosa in relation to
methacholine dose-response curves in atopic asthma
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CORNELIA G. VAN HELDEN-MEEUWSEN,2 HENK C. HOOGSTEDEN,1
AND JAN M. BOGAARD1
Departments of 1Pulmonary Diseases and 2Immunology, Erasmus University Rotterdam,
University Hospital Dijkzigt, 3015 GD Rotterdam, The Netherlands
Mo¨ller, Gertrude M., Shelley E. Overbeek, Cornelia
G. Van Helden-Meeuwsen, Henk C. Hoogsteden, and
Jan M. Bogaard. Eosinophils in the bronchial mucosa in
relation to methacholine dose-response curves in atopic
asthma. J. Appl. Physiol. 86(4): 1352–1356, 1999.—Asthma
is characterized by both local infiltration of eosinophils in the
bronchial mucosa and bronchial hyperreactivity (BHR). A
detailed characterization of BHR implies analysis of a hista-
mine or methacholine dose-response curve yielding not only
the dose at 20% fall of baseline forced expiratory volume in 1 s
(FEV1), but also a plateau (P) representing the maximal
narrowing response in terms of percent change in FEV1 and
reactivity as the steepest slope at 50% of P (%FEV1/doubling
dose). In the baseline condition, the specific airway conduc-
tance (sGaw) may be considered closely related to airway
lumen diameter. In 20 nonsmoking asthmatic patients, metha-
choline dose-response curves were obtained, and a sigmoid
model fit yielded the BHR indexes. Immunohistochemistry
with the monoclonal antibodies (EG1 and EG2) was used to
recognize the total number of eosinophils and activated
eosinophils, respectively. The number of activated eosinophils
was significantly correlated to both P (r 5 0.62; P , 0.05) and
sGaw (r 5 20.52; P , 0.05), whereas weaker and nonsignifi-
cant correlations were found for dose at 20% fall of baseline
FEV1 and the total number of eosinophils. We conclude that
the number of activated eosinophils can be considered a
marker of the inflammation-induced decrease of airway lu-
men diameter as represented by the plateau index and sGaw.
bronchial mucosa; bronchial hyperreactivity; methacholine
dose-response curve
ATOPIC ASTHMA IS CHARACTERIZED by local infiltration of
several activated inflammatory cells in the bronchial
mucosa, even in subjects with mild asthma (6). Airway
inflammation produces hyperemia in the lamina pro-
pria (27). The process of vasodilation and plasma
leakage may increase airway wall thickness, which
may directly contribute to airway narrowing (24, 27).
Eosinophils in particular have been associated with
epithelial damage (5, 14) through their release of
different basic proteins with cytotoxic properties, such
as major basic protein, eosinophil cationic protein
(ECP), eosinophil-derived neurotoxin, and eosinophil
peroxidase. The number of eosinophils in the bronchial
mucosa and in bronchoalveolar lavage fluid has been
correlated with the severity of asthma and the mecha-
nisms that underlie airway hyperresponsiveness (4, 18,
25, 26), one of the most prominent characteristics of
asthma (3).
Airway hyperresponsiveness is accompanied by a
decrease in the threshold of airway narrowing in
response to a variety of nonspecific stimuli (15). At
present, airway responsiveness is usually measured in
dose-response curves as the provocative concentration
(PC) of histamine or methacholine causing a fall of 20%
in the forced expiratory volume in 1 s (FEV1), which is
called the sensitivity (S; log2 PC20). Previous studies
(12, 22) have focused on the importance of characteriz-
ing the entire histamine or methacholine dose-response
(MDR) curve not only by S, but also by reactivity,
defined as the slope at 50% of the curve (R; %FEV1/
doubling dose), and the maximal airway narrowing
response value [plateau (P); %change in FEV1]. It was
found that dose-response curves from asthmatic sub-
jects show a shift to the left and have a steeper slope
and higher maximal response value compared with
those of normal subjects (28). To interpret the entire
dose-response curve accurately, a model fit to the
data is often necessary. Reaching an experimental P
may be associated with a large drop in FEV1, causing
feelings of severe dyspnea in the patient and making
the measurement very uncomfortable for the pa-
tient. Extrapolation of the data may, therefore, be
necessary. Moreover, the model gives a smoothing of
the individual data fluctuations, because of varying
levels of patient cooperation or other causes. In our
investigation, indexes were obtained as parameters of a
sigmoid model, the cumulative Gaussian distribution
(CGD) function, which was fitted to the dose-response
curves (1).
Indexes of the MDR curve, which describe different
aspects of bronchial hyperreactivity (22), may be corre-
lated with inflammatory cell numbers. Another lung
function index, which is an indicator of the size of the
airway lumen, is the specific (volumic) airway conduc-
tance (sGaw; Ref. 29) to be obtained by body plethysmog-
raphy. Inflammation, contributing to airway narrow-
ing, may also be correlated with this variable. We,
therefore, tested the hypothesis that, in mild to moder-
ate asthma, indexes from the entire MDR curves and
baseline sGaw are related to the presence and activa-
tion of eosinophils in the lamina propria.
METHODS
Patients. Patients were selected when they met the follow-
ing criteria during the baseline measurements: PC20 hista-
mine # 8 mg/ml and $9% reversibility in FEV1, relative to
The costs of publication of this article were defrayed in part by the
payment of page charges. The article must therefore be hereby
marked ‘‘advertisement’’ in accordance with 18 U.S.C. Section 1734
solely to indicate this fact.











baseline, after inhalation of 1,000 µg of b2-adrenoceptor
agonists. Atopy was defined by at least one positive skin-prick
test to a panel of 16 common aeroallergens in the presence of
positive and negative controls.
In the month preceding the baseline measurements, pa-
tients were only allowed to take inhaled short-acting b2-
agonists on an as-needed basis. All other medication was
stopped. Patients with a history suggesting respiratory infec-
tion or exacerbation of asthma in the month before the study
were excluded.
Twenty nonsmoking atopic asthmatic patients [15 men;
median age 26 yr (range 21–56 yr)] entered the study. Median
FEV1 was 2.98 liters (range 1.94–5.36 liters), and for percent
predicted the median was 87% (range 47–108%). Approval
was obtained by the Medical Ethics Committee of the hospi-
tal. All patients gave informed consent.
Design. After the first visit, baseline values were estab-
lished during two morning or afternoon sessions. At one of
these sessions, a flow-volume curve was constructed, broncho-
dilator response was measured, and intradermal skin testing
was performed; at the other session, body plethysmography
was carried out followed by the methacholine provocation
test. Bronchoscopy was performed 1 wk after the baseline
visit and was performed by the same operator (S. E. Over-
beek).
Bronchoscopy. Fiber-optic bronchoscopy (model BF IT 10,
Olympus, Tokyo, Japan) was performed with atropine (0.5 mg
im) as premedication. Terbutaline, two puffs of 250 µg per
nebuhaler, was given 30 min before the procedure. The nose,
throat, and vocal cords were anesthetized with topical lido-
caine spray. An Olympus fenestrated forceps (model FB19C)
was used to take three to six biopsies from segmental or
subsegmental divisions of the main bronchi.
Immunohistochemistry of bronchial biopsies. Each biopsy
specimen was immediately placed in isotonic saline and
frozen within 20 min in Tissue-Tek OCT embedding medium
(Miles, Naperville, IL). Samples were stored at 280°C until
use.
Sections (6 µm) were cut by using a cryostat and were
collected on poly-L-lysine-coated (Sigma Chemical, St. Louis,
MO) slides. The sections were air-dried for at least 1 h and
stored at 220°C until use. Before immunohistological stain-
ing, frozen tissue sections were brought to room temperature
and fixed in acetone for 10 min.
Immunohistochemical staining of bronchial biopsies was
performed with the immuno-alkaline phosphatase anti-
alkaline phosphatase method (9) by using new fuchsin
(Chroma-Gesellschaft, Stuttgart, Germany) as the chroma-
gen.
The following monoclonal antibodies were used: EG1, recog-
nizing ECP in resting and activated eosinophils, and EG2,
recognizing the cleaved form of ECP in activated eosinophils
(Pharmacia, Uppsala, Sweden). The dilution was 1:100 for
both EG1 and EG2.
Control slides were treated similarly excluding the pri-
mary antibody and by using an unrelated antibody of the
same isotype and concentration.
The interval between the sections was at least 12 µm to
avoid overlapping of cells.
Quantification of eosinophils. In the majority of cases, two
biopsy specimens, out of three to six biopsies taken, were
coded, and the observer (G. M. Mo¨ller) counted 5–10 sections
in a blinded fashion for each antibody and each biopsy at a
magnification of 3400 (Zeiss microscope 903844). Thus the
total number of sections for the n 5 20 patients per marker
was ,300, and per-patient mean values were calculated.
With the use of an eyepiece graticule, the number of posi-
tively stained cells was counted in a zone 100 µm deep in the
lamina propria along the length of the epithelial basement
membrane (BM), which had to be covered with epithelium
over at least 500 µm. Most of the biopsies were of adequate
size, without crush artifacts. Cells were counted if they
stained red and contained a nucleus. The cell counts were
expressed as the number of cells per millimeter of BM. The
within-observer x2 test for goodness of fit for three repeated
counts was ,5% for EG1 and EG2.
Quantification of the lamina reticularis. Biopsies were
coded before analysis. Subepithelial reticular collagen thick-
ness was measured by using a 10 3 100 oil objective and a
digital image-processing system (IBAS 2000 system, Kon-
tron, Munich, Germany). The thickness of the BM was
quantitated by measuring only the BM covered by at least a
basal epithelial cell layer and where the lamina propria
under the BM was at least 100 µm deep. The thickness of the
BM was measured in five random fields in two sections for
each patient.
MDR curves. The methacholine challenge test was per-
formed by using the standardized 2-min tidal-breathing
technique (8). Dose-response (%FEV1) curves were obtained
after the patients inhaled doubling concentrations of acetyl-b-
methylcholine bromide (0.03–256 mg/ml) in normal saline.
Dose was expressed as the log2 of the methacholine concentra-
tion in milligrams of methacholine per milliliter of saline.
Thus 1 mg/ml is equivalent to 0.82 mg/ml of methylcholine-
chloride solution. When chloride and bromide data are com-
pared, a fixed conversion constant of 0.29 should, therefore,
be subtracted from the log2 dose bromide values. A test was
interrupted if the FEV1 fell by more then 60% or if unpleasant
side effects or dyspnea compelled the patient to stop.
Curve fitting. Although S was obtained by linear interpola-
tion of adjacent data points of the dose-response curve
according to international standards (19), other indexes of the
sigmoid curve were obtained by fitting with a CGD function
(1). This fit yielded the R as slope in the 50% point of the curve
(%FEV1/doubling dose) and the P value. If the last three PC
values showed a variation coefficient of ,5% of the mean
value, this mean value was considered as the experimental P
estimate; otherwise, the model fit was used from which the
extrapolated P value was obtained. For R only, model esti-
mates were used.
Pulmonary function. FEV1 was measured with a heated
pneumotachometer system (Jaeger, Wu¨rzburg, Germany),
corrected to BTPS conditions and expressed as percent pre-
dicted (19).
sGaw was measured in a volume-constant body plethysmo-
graph (Jaeger body test). The value was derived from the
ratio of the inverse of the effective resistance (Reff) and the
intrathoracic gas volume during the measurement. Body
plethysmography was assessed with a humidified and ther-
mostated (37°C) rebreathing bag during normal breathing,
whereas panting frequency during the volume measurement
was ,0.5–1 Hz.
Data analysis. Correlation coefficients between cellular
and pulmonary function indexes were obtained by Spear-
man’s rank method; P , 0.05 was considered significant.
RESULTS
Curve fitting and sGaw. In 12 patients, the P value
had to be obtained with the model fit because experimen-
tal determination was not possible. An example of a P
extrapolation by a model fit is given in Fig. 1. Median
values and ranges of R and P values were 9.06%
FEV1/doubling dose (range 3.31–16.7% FEV1/doubling











dose) and 52.95% FEV1 (range 23.8–80.5% FEV1),
respectively. Median and range of log2 PC20 and sGaw
were 0.08 mg/ml (range 25.18–7.98 mg/ml) and 0.63
s/kPa (range 0.25–2.28 s/kPa), respectively.
Correlation among cellular indexes, FEV1, hyperre-
sponsiveness, and sGaw. The median values and ranges
for EG11 (total) eosinophils and EG21 (activated) eosino-
phils were 11.6 cells/mm BM (range 1.6–68 cells/mm
BM) and 3.5 cells/mm BM (range 0–29.3 cells/mm BM),
respectively. The correlation among the log dose-re-
sponse indexes, sGaw, and (activated) eosinophils is
indicated in Table 1.
The median thickness of the BM was 10.6 µm (range
6.1–14.5 µm). BM thickness was not significantly corre-
lated with lung function or dose-response indexes.
The correlation between baseline FEV1 (%predicted)
and cellular or dose-response indexes was also not
significant.
In addition, we found no significant correlation be-
tween the total number of eosinophils (EG11) and log2
PC20 or R. However, the number of activated eosino-
phils (EG21) was, although weakly, significantly corre-
lated to the P value (Table 1: r 5 0.62, P , 0.05; Fig. 2).
No correlation was found between the total number of
eosinophils and the P value. The sGaw was negatively
correlated with the number of activated eosinophils
(Table 1; r 5 20.52, P , 0.05) but not with the total
eosinophil number.
DISCUSSION
In the present study, we have demonstrated a signifi-
cantly positive correlation between the number of
activated eosinophils in the lamina propria, an impor-
tant cellular marker in bronchial mucosal inflamma-
tion, and the P value. Furthermore, the sGaw was
significantly negatively correlated with the number of
activated eosinophils. No significant correlations could
be demonstrated between basal membrane thickness
and either lung function or dose-response indexes.
In a previous study (1), our laboratory has shown
that our model was preferable to other methods, which
mostly used only part of the data points. The CGD
model both enabled smoothing out of random fluctua-
tions in the data points and yielded reliable curve
indexes (R and P value) where no experimental P
values could otherwise be reached. In eight of the MDR
curves in this study, a P could be accurately estimated
by averaging the last three PC values. In the other
cases, the value had to be extrapolated with the CGD
model fit.
Interestingly, only the number of activated eosino-
phils, not the total number, was significantly correlated
with the P value. In previous studies with bronchial
biopsies from asthmatic patients, the relationship be-
tween eosinophils and the degree of airway hyperrespon-
siveness (PC20 methacholine) has been investigated.
Bradley et al. (6) have found a negative correlation
Fig. 1. Example of curve fit with cumulative Gaussian distribution
function to a methacholine bromide dose-response curve. Plateau was
obtained by extrapolation. Dose values are presented as methacho-
line chloride equivalents. FEV1, forced expiratory volume in 1 s.
Table 1. Spearman rank correlation coefficients
between number of total and activated eosinophils and
sensitivity (log2 PC20), reactivity (%FEV1/doubling
dose), plateau value, and specific airway conductance
log2 PC20 Reactivity Plateau sGaw
EG11 20.10 0.28 0.37 20.40
EG21 20.32 0.12 0.62* 20.52*
PC20, provocative concentration that causes 20% fall of baseline
forced expiratory volume in 1 s (FEV1); sGaw, specific airway
conductance; EG11, total eosinophils (n520); EG21, activated eosino-
phils (n520). *P , 0.05.
Fig. 2. Plateau values in relation to number of activated (EG21)
eosinophils per millimeter of basement membrane (BM) (r 5 0.62,
P , 0.05).











between the number of EG21 eosinophils and log2 PC20
when comparing subjects with asthma with control
subjects. Djukanovic et al. (11), however, were unable
to demonstrate a correlation between the number of
activated eosinophils and PC20 methacholine, and nei-
ther were we.
A recent study (7) showed a significant negative
correlation between the total number of intraepithelial
eosinophils and PC20 methacholine values. These find-
ings were in line with another study (13) that showed
that the total number of inflammatory cells and mast
cells was significantly negatively correlated with PC20
methacholine. Although we also found negative correla-
tion coefficients for the relationship between log2 PC20
and both the total number of eosinophils and the
number of activated eosinophils, these coefficients did
not reach significance. Although a reasonable number
of sections per patient were analyzed, the relatively
small sample size and random measuring errors may
have influenced the correlations. Jeffery et al. (17) have
found that counting all the inflammatory cells, not only
in the lamina propria but also in the submucosa, did
not improve correlations. It is, therefore, unlikely that
the fact that we restricted our findings to the lamina
propria may have influenced the correlations.
The maximal response P has been considered as
determined by ‘‘postjunctional’’ mechanisms, such as
smooth muscle contractility, viscous and elastic loads
on airway smooth muscle shortening, swelling of the
airway wall, and intraluminal exudate (22). The signifi-
cant relationship of the number of activated eosinophils
with the P value may reflect the influence of inflamma-
tion on airway lumen, in this case being the residual
lumen after maximal bronchoconstriction. S changes
are associated with a horizontal shift of MDR curves, as
shown in Fig. 1. The position with respect to the log
dose axis is then most accurately defined as the PC at
50% of the P value. This means that log2 PC20 is
dependent not only on the position of the curve along
the horizontal axis but also on the P value. We found, on
one hand, a nonsignificant relationship between EG21
and log2 PC20 but, on the other hand, a significant
correlation between EG21 and P. Thus most probably
the primary EG21-related effect was on airway lumen
diameter and not on S.
We used sGaw, derived from Reff and intrathoracic
gas volume, as another index, being representative of
the size of the airway lumen. No unique index for
resistance exists in cases of unequal ventilation, which
may be present in the patient category we investigated.
Mean resistance within the breathing cycle is then best
represented by Reff (16). Moreover, sGaw is less depen-
dent on lung volume than are other resistance indexes.
The significant relationship that we found between
sGaw and the number of activated eosinophils, indicat-
ing that a decrease in specific conductance coincides
with an increase in the number of activated eosino-
phils, can also possibly be explained by the swelling of
the airway wall and the presence of intraluminal
exudate. The weaker correlation of EG21 with FEV1
(%predicted) may probably be explained by the fact
that this variable is less directly related to airway
lumen or various aspects of lung mechanics, e.g., elastic
properties of lung parenchyma and central airways.
Our findings support suggestions put forward in a
recent study by Crimi et al. (10). Similar to our
findings, they did not find a correlation between ECP
contents and PC20. They suggested that airway remod-
eling may play a role. The correlations we found
between activated eosinophils and both P and sGaw do
support their suggestions.
Although Jeffery et al. (17) state that it is more
appropriate to look at relative proportions of various
inflammatory cells present rather than at the total
number of activated eosinophils, we found no signifi-
cant correlations between cells as antigen-presenting
cells (CD1a1 cells), T lymphocytes (CD41 cells), and
mast cells (tryptase1 cells) on bronchial hyperreactivity
or lung function indexes (data not shown).
We only investigated eosinophils in bronchial biop-
sies and not in bronchoalveolar lavage fluid or sputum.
Earlier investigations in bronchial lavage fluid also
found the degree of eosinophil activation, rather then
the total number of eosinophils, to reflect inflammation
in asthma (2). The same conclusion was drawn from
studies in sputum (20, 23). Our findings, therefore,
support the hypothesis that activated eosinophils and/or
their mediators cause bronchoconstriction, enhance
airway inflammation and epithelial damage, and possi-
bly cause an increase in airway hyperresponsiveness.
In conclusion, the P value and also baseline sGaw are
weakly, although significantly, related to the number of
activated eosinophils in the bronchial mucosa. These
results suggest a direct relationship between bronchial
mucosal inflammation characterized by eosinophil acti-
vation and the decrease in airway lumen. Our results
stress the importance of modeling the entire MDR
curve when characterizing airway hyperresponsive-
ness in patient follow-up.
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